Browse SRPX2

Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Cytoplasm. Cell surface. Cell junction, synapse
Domain PF13778 Domain of unknown function (DUF4174)
PF02494 HYR domain
PF00084 Sushi repeat (SCR repeat)
Function

Acts as a ligand for the urokinase plasminogen activator surface receptor. Plays a role in angiogenesis by inducing endothelial cell migration and the formation of vascular network (cords). Involved in cellular migration and adhesion. Increases the phosphorylation levels of FAK. Interacts with and increases the mitogenic activity of HGF. Promotes synapse formation. May have a role in the perisylvian region, critical for language and cognitive development.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001667 ameboidal-type cell migration
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0007416 synapse assembly
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0030335 positive regulation of cell migration
GO:0040017 positive regulation of locomotion
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044089 positive regulation of cellular component biogenesis
GO:0044708 single-organism behavior
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0048514 blood vessel morphogenesis
GO:0050803 regulation of synapse structure or activity
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0051272 positive regulation of cellular component movement
GO:0051962 positive regulation of nervous system development
GO:0051963 regulation of synapse assembly
GO:0051965 positive regulation of synapse assembly
GO:0071625 vocalization behavior
GO:0090049 regulation of cell migration involved in sprouting angiogenesis
GO:0090050 positive regulation of cell migration involved in sprouting angiogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:1901342 regulation of vasculature development
GO:1903670 regulation of sprouting angiogenesis
GO:1903672 positive regulation of sprouting angiogenesis
GO:1904018 positive regulation of vasculature development
GO:2000147 positive regulation of cell motility
Molecular Function GO:0019838 growth factor binding
GO:0036458 hepatocyte growth factor binding
Cellular Component GO:0060076 excitatory synapse
GO:0097060 synaptic membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SRPX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SRPX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SRPX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.5140.0214
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.9590.0428
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4450.679
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4210.348
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9750.658
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2670.916
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0320.958
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1510.886
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0370.975
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0890.364
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.5790.11
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3840.0236
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SRPX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRPX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRPX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRPX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRPX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SRPX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SRPX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSRPX2
Namesushi-repeat containing protein, X-linked 2
Aliases SRPUL; sushi-repeat-containing protein, X-linked 2; BPP; CBPS; PMGX; RESDX; sushi-repeat protein up-regulate ......
Chromosomal LocationXq22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SRPX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.